The accessible cerebral vascular proteome in a mouse model of cerebral β-amyloidosis.
Assessing protein changes in the cerebral vasculature of brain disorders may increase our understanding of disease pathogenesis and facilitate diagnostic and therapeutic intervention. By combining perfusion of mice with a charged reactive biotin derivative and subsequent quantification of the biotinylated proteins, the proteome accessible from the vasculature in an APPPS1 transgenic mouse model of cerebral β-amyloidosis was identified and compared to that in non-transgenic control mice. Our results provide proof-of-concept of this technology for the identification of new targets for antibody-based therapy or pharmacodelivery, and for neuroimaging in neurodegenerative diseases.
Department of Chemistry and Applied Biosciences, ETH Zürich, Zurich, Switzerland. christoph.roesli@pharma.ethz.ch
Christoph
C
Roesli
Tim
T
Fugmann
Beatrice
B
Borgia
Christoph
C
Schliemann
Dario
D
Neri
Mathias
M
Jucker
D016229:Amyloid beta-Peptides / Q000235:genetics / Q000378:metabolism; D000686:Amyloidosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D001808:Blood Vessels / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D002540:Cerebral Cortex / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008954:Models, Biological; D020543:Proteome / Q000032:analysis* / Q000378:metabolism
D016229:Amyloid beta-Peptides; D020543:Proteome